Correlations between chromosomal abnormalities and clinical stages
| Chromosomal abnormalities . | MGUS (n = 147) (%) . | SMM (n = 39) (%) . | MGUS/SMM (n = 186) . | MM (n = 669) (%) . | Primary PCL (n = 46) . | ||
|---|---|---|---|---|---|---|---|
| No. (%) . | P* . | No. (%) . | P* . | ||||
| 14q32 rearrangements† | 69/143 (48) | 18/38 (47) | 87/181 (48) | < 10−9 | 477/653 (73) | 38/45 (84) | NS |
| t(11;14) | 19/147 (13) | 9/39 (23) | 28/186 (15) | NS | 105/669 (16) | 15/46 (33) | .006 |
| t(4;14) | 3/147 (2) | 1/39 (3) | 4/186 (2) | < .001 | 68/669 (10) | 6/46 (13) | NS |
| t(14;16) | 1/147 | 0/39 | 1/186 (< 1) | NS | 14/669 (2) | 5/46 (11) | .002 |
| del(13) | 31/147 (21) | 11/39 (28) | 42/186 (23) | < 10−6 | 288/669 (43) | 32/46 (70) | < .001 |
| Chromosomal abnormalities . | MGUS (n = 147) (%) . | SMM (n = 39) (%) . | MGUS/SMM (n = 186) . | MM (n = 669) (%) . | Primary PCL (n = 46) . | ||
|---|---|---|---|---|---|---|---|
| No. (%) . | P* . | No. (%) . | P* . | ||||
| 14q32 rearrangements† | 69/143 (48) | 18/38 (47) | 87/181 (48) | < 10−9 | 477/653 (73) | 38/45 (84) | NS |
| t(11;14) | 19/147 (13) | 9/39 (23) | 28/186 (15) | NS | 105/669 (16) | 15/46 (33) | .006 |
| t(4;14) | 3/147 (2) | 1/39 (3) | 4/186 (2) | < .001 | 68/669 (10) | 6/46 (13) | NS |
| t(14;16) | 1/147 | 0/39 | 1/186 (< 1) | NS | 14/669 (2) | 5/46 (11) | .002 |
| del(13) | 31/147 (21) | 11/39 (28) | 42/186 (23) | < 10−6 | 288/669 (43) | 32/46 (70) | < .001 |
MGUS indicates monoclonal gammopathy of undetermined significance; SMM, smoldering multiple myeloma; MM, multiple myeloma; PCL, plasma cell leukemia; and NS, not significant.
For difference with MM.
Patients with monosomy 14 were considered noninformative for this item and were excluded from analysis.